Predictors of mortality in Middle East respiratory syndrome (MERS)
- 19 July 2017
- Vol. 73 (3), 286-289
- https://doi.org/10.1136/thoraxjnl-2016-209313
Abstract
We evaluated the clinical characteristics, cytokine/chemokine concentrations, viral shedding and antibody kinetics in 30 patients with Middle East respiratory syndrome (MERS), including 6 non-survivors admitted to 3 MERS-designated hospitals. Old age, low albumin, altered mentality and high pneumonia severity index score at admission were risk factors for mortality. In addition, severe signs of inflammation at initial presentation (at hospital days 1-4), such as high inducible protein-10 (p=0.0013), monocyte chemoattractant protein-1 (p=0.0007) and interleukin 6 (p=0.0007) concentrations, and poor viral control (high viral load at hospital days 5–10, p<0.001) without adequate antibody titres (low antibody titre at hospital days 11–16, p=0.07) during the course of disease, were associated with mortality.Keywords
Funding Information
- the Ministry of Health & Welfare, Republic of Korea
- The Ministry of Science, ICT and Future Planning, Republic of Korea
- A grant funded from the As an Institute for Life Science
This publication has 7 references indexed in Scilit:
- Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severityScientific Reports, 2016
- Inactivation and safety testing of Middle East Respiratory Syndrome CoronavirusJournal of Virological Methods, 2015
- Severe acute respiratory syndrome vs. the Middle East respiratory syndromeCurrent Opinion in Pulmonary Medicine, 2014
- Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?PLOS ONE, 2014
- Characterization of Cytokine/Chemokine Profiles of Severe Acute Respiratory SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2005
- An interferon‐γ‐related cytokine storm in SARS patientsJournal of Medical Virology, 2004
- Plasma inflammatory cytokines and chemokines in severe acute respiratory syndromeClinical and Experimental Immunology, 2004